New typhoid conjugate vaccine shows safety and strong immune response in Africa

Post author:admin
Post published:November 12, 2025
Post category:uncategorized

PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.®

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Climate change boosts infectious disease spread, hits the vulnerable hardest

Study highlights barriers to Alzheimer’s care in rural Georgia

Sharing positive palliative care stories to improve rural end-of-life support

Helpful Links

Subscribe To Us